169 related articles for article (PubMed ID: 36251462)
1. Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.
Mielnik CA; Li CK; Ramsey AJ; Salahpour A; Burnham WM; Ross RA
Cannabis Cannabinoid Res; 2024 Feb; 9(1):174-187. PubMed ID: 36251462
[No Abstract] [Full Text] [Related]
2. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
5. Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101.
Stollenwerk TM; Pollock S; Hillard CJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500787
[TBL] [Abstract][Full Text] [Related]
6. The effects of cannabidiol and Δ9-tetrahydrocannabinol, alone and in combination, in the maximal electroshock seizure model.
Dlugosz L; Zhou HZ; Scott BW; Burnham M
Epilepsy Res; 2023 Feb; 190():107087. PubMed ID: 36646020
[TBL] [Abstract][Full Text] [Related]
7. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
[TBL] [Abstract][Full Text] [Related]
8. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
Hahn B
Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
[TBL] [Abstract][Full Text] [Related]
9. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
Arnold JC; Boucher AA; Karl T
Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
11. The effects of preventative cannabidiol in a male
Visini G; Brown S; Weston-Green K; Shannon Weickert C; Chesworth R; Karl T
Front Cell Neurosci; 2022; 16():1010478. PubMed ID: 36406747
[TBL] [Abstract][Full Text] [Related]
12. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
13. Interactions between cannabidiol and Δ
Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
[TBL] [Abstract][Full Text] [Related]
14. Δ
Hodges RM; Chase KJ; Tripson MA; Bingham S; Woolley-Roberts M; Guy GW; Soderstrom K
Cannabis Cannabinoid Res; 2023 Oct; 8(5):790-801. PubMed ID: 36125410
[No Abstract] [Full Text] [Related]
15. Effects of cannabidiol and Δ9-tetrahydrocannabinol in the elevated plus maze in mice.
Liu J; Scott BW; Burnham WM
Behav Pharmacol; 2022 Apr; 33(2&3):206-212. PubMed ID: 33883447
[TBL] [Abstract][Full Text] [Related]
16. Perspectives toward cannabidiol (CBD) among youth in Early Psychosis Intervention programs: A qualitative study.
Ghelani A
Early Interv Psychiatry; 2024 Jan; 18(1):10-17. PubMed ID: 37038248
[TBL] [Abstract][Full Text] [Related]
17. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
Hempel BJ; Clasen MM; Nelson KH; Woloshchuk CJ; Riley AL
Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
Hudson R; Renard J; Norris C; Rushlow WJ; Laviolette SR
J Neurosci; 2019 Oct; 39(44):8762-8777. PubMed ID: 31570536
[TBL] [Abstract][Full Text] [Related]
19. Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
Al-Ghezi ZZ; Miranda K; Nagarkatti M; Nagarkatti PS
Front Immunol; 2019; 10():1921. PubMed ID: 31497013
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]